Nexstim Receives an NBS System Order from a Customer in Europe
Nexstim Receives an NBS System Order from a Customer in Europe
Press release, Helsinki, 25August 2022 at 10AM (EET)
Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") has received an NBS 5 System order from a customer in Europe. The customer is a new user of the Nexstim NBS system, acquiring the system to enable future neuroscience projects.
Nexstim’s SmartFocus® nTMS (navigated transcranial magnetic stimulation) technology enables accurate and personalized stimulation, considering the unique shape and conductivity of each patient’s brain. Nexstim’s NBS (Navigated Brain Stimulation) system is used, for example, in planning neurosurgery and in the case of this customer enables neuroscience studies where the stimulation needs to be targeted individually to the brain, reproducing the pulse delivery reliably for diagnosis.
This specific NBS system also includes the software of an NBT® (Navigated Brain Therapy) system, allowing it to also be used for the treatment of major depression and chronic neuropathic pain.
Mikko Karvinen, CEO of Nexstim, comments: “Nexstim has been actively working as a partner in TMS-EEG development. TMS-evoked EEG responses are sensitive to even the smallest shifts in stimulation location. While allowing highly location-specific data to be gathered, this also makes a reliable, precise and accurate navigation solution imperative for TMS-EEG measurements and even more so when studies require repeatability and reproducibility.We are very happy to see that our development work at Nexstim results in enabling new customers to use our world-leading technology in their neuroscience research projects.”
Further information is available on the website www.nexstim.com, or by contacting:
Mikko Karvinen, CEO
+358 50 326 4101
About Nexstim Plc
Nexstim is a Finnish, globally operating growth-oriented medical technology company. Our mission is to enable personalized and effective diagnostics and therapies for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology for navigated transcranial magnetic stimulation (nTMS) with highly sophisticated 3D navigation providing accurate and personalized targeting of the TMS to the specific area of the brain.
Nexstim’s Diagnostics Business focuses on commercialization of the Navigated Brain Stimulation (NBS) system. The NBS system is the only FDA cleared and CE marked navigated TMS system for pre-surgical mapping of the speech and motor cortices of the brain.
Nexstim’s Therapy Business markets and sells the Navigated Brain Therapy (NBT®) system, which is FDA cleared for marketing and commercial distribution for the treatment of major depressive disorder (MDD) in the United States. In Europe, the NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
Nexstim shares are listed on the Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
For more information, please visit www.nexstim.com
AttachmentTo view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
AB Linas Agro Group: notification on disposal of voting rights4.12.2023 17:34:50 CET | Press release
AB Linas Agro Group, ISIN code LT0000128092 (hereinafter - the Company), received notification from UAB “INVL Asset Management” on the disposal of voting rights (enclosed). Additional information: Mažvydas Šileika, Finance Director of AB Linas Agro Group Mob. +370 619 19 403 E-mail email@example.com Attachment Notification on disposal of block of shares_UAB INVL Asset Management
Innofactor Plc: Share Repurchase 4.12.20234.12.2023 17:30:00 CET | Press release
Innofactor Plc Announcement 4.12.2023Innofactor Plc: Share Repurchase 4.12.2023In the Helsinki Stock ExchangeTrade date 4.12.2023Bourse trade BuyShare IFA1VAmount 4,700SharesAverage price/ share 1.1600EURTotal cost 5,452.00EURInnofactor Plc now holds a total of 566 529 sharesincluding the shares repurchased on 4.12.2023On behalf of Innofactor PlcNordea Bank OyjJanne Sarvikivi Sami HuttunenAdditional information:Sami Ensio, CEOInnofactor PlcTel. +358 50 584 firstname.lastname@example.org Attachment Innofactor_4.12_trades
Borregaard ASA: Share buy-back programme completed4.12.2023 16:58:26 CET | Press release
04.12.2023: Borregaard ASA (”Borregaard”, OSE ticker: BRG) Reference is made to the stock exchange notice of 17 November 2023 where Borregaard announced the intent to repurchase up to 200,000 of its outstanding common stock. The repurchase of shares will be conducted in a period from 20th November up to and including 20th December 2023 at the latest. Borregaard has in the period from 29 November up to and including 4 December in total purchased 60,204 own shares through broker at an average price of NOK 173.24 per share. By these transactions, Borregaard has completed its share buy-back programme by repurchasing 200,000 shares of its outstanding common stock. Aggregated overview of transactions per day: DateAggregated daily volume (number of shares)Weighted average share price per day (NOK)Total daily transaction value (NOK)29.11.20239,142173.32161,584,506.0730.11.202317,258172.80752,982,311.8401.12.202316,902172.73082,919,495.9804.12.202316,902174.14862,943,459.64Previously disclosed
BBS-Bioactive Bone Substitutes Plc: Managers' Transactions - Pekka Jalovaara4.12.2023 15:45:00 CET | Press release
BBS-Bioactive Bone Substitutes Plc, Company announcement, Management transactions, 4 December 2023 at 4.45 p.m. (EET) BBS-Bioactive Bone Substitutes Oyj - Managers' Transactions – Pekka Jalovaara ____________________________________________ Person subject to the notification requirement Name: Jalovaara Pekka Position: Member of the Board/Deputy member Issuer: BBS Bioactive Bone Substitutes Oyj LEI: 743700BYSBP0PCR6N767 Notification type: INITIAL NOTIFICATION Reference number: 743700BYSBP0PCR6N767_20231203205051_6 ____________________________________________ Transaction date: 2023-11-30 Venue not applicable Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT ISIN: FI4000260583 Nature of the transaction: DISPOSAL Transaction details (1): Volume: 126,606 Unit price: 0.005012 EUR Aggregated transactions (1): Volume: 126,606 Volume weighted average price: 0.005012 EUR ____________________________________________ Person subject to the notification requirement Name: J
AB Linas Agro Group: notification on acquisition of block of shares of the Company4.12.2023 15:21:52 CET | Press release
AB Linas Agro Group, ISIN code LT0000128092 (hereinafter - the Company), received a notification from UAB “SB Asset Management” on the acquisition of block of shares and voting rights of the Company (enclosed). Additional information: Mažvydas Šileika, Finance Director of AB Linas Agro Group Mob. +370 619 19 403 E-mail email@example.com Attachment Notification-of-aquisition-of-block-of-shares LNA-s1204